Articles tagged with Cancer Medication
A team of scientists has discovered a compound named triptolide, isolated from the thunder god vine, which is far more potent than current therapies against hepatocellular carcinoma. The researchers used nanotechnology to improve delivery and reduce toxicity, showing increased efficacy in tumor accumulation and uptake into cancer cells.
A new study from Johns Hopkins Medicine suggests that nearly half of African-Americans may not receive effective doses of the HIV drug maraviroc due to their genetic makeup. Researchers developed a simple genetic test to determine individual dosage needs, which could help improve treatment outcomes.
Researchers have developed a new method to identify and measure vital molecules that control cell behavior, paving the way for better diagnosis, prediction, and monitoring of cancer. The study identified over 200 protein kinases and created a technique to quantify their levels in biological samples.
Researchers have found that cancers exhibit distinct patterns of methylation on the DNA genome, enabling tumor cells to turn genes on or off as needed. These epigenetic changes allow cancer cells to adapt and spread, making them a key factor in tumor development.
Researchers have discovered over 30 enzyme-blocking molecules that can curb malaria before symptoms start, targeting the liver stage of the parasite's lifecycle. These protein kinase inhibitors, also used to treat cancer, could diversify the antimalarial arsenal and extend the lifespan of existing drugs.
A team of scientists discovered that a drug originally designed for DNA repair defects could potentially be used to treat leukemia and other cancers. Combining PARP inhibitors with standard chemotherapy drugs showed promise in combating the disease, with potential applications for other common cancers.
A team of scientists sequenced chromophobe renal cell carcinoma tumors and found unique alterations involving telomerase, a gene that plays a critical role in cell division. This discovery provides new clues about the disease's biology and may lead to the development of targeted therapies for this rare type of kidney cancer.
Patients with advanced laryngeal cancer who underwent surgery had significantly better disease-specific and overall survival rates compared to those treated with nonsurgical chemoradiation. The study analyzed data from over 5,000 patients diagnosed between 1992 and 2009.
Scientists have discovered that blocking nerve signals using surgery or Botox can slow stomach cancer growth and increase survival rates in mice. This finding offers a promising new treatment approach for this devastating disease, which affects over 2 million people worldwide.
Researchers, led by UC Santa Cruz's Seth Rubin, are developing a new class of drugs to treat breast cancer by targeting the inactivated retinoblastoma tumor suppressor protein. The innovative approach may have fewer toxic side effects and be less vulnerable to drug resistance.
Researchers at VCU Massey Cancer Center found that protein AEG-1 interferes with retinoic acid's ability to treat leukemia and liver cancer, highlighting a potential target for new therapies. The study's results could impact the treatment of countless cancer patients by enabling doctors to screen for AEG-1 expression levels.
Scientists at Scripps Research Institute have successfully disrupted MYC, a cancer regulator thought to be undruggable, using a credit card-like molecule called KJ-Pyr-9. This breakthrough discovery shows the drug candidate can stop tumor growth in animal models and may offer new hope for cancer treatment.
A new study led by researchers at UCSF analyzed the effect of two widely used osteoporosis drugs on breast cancer risk in post-menopausal women. The findings suggest that low estrogen levels, rather than the drugs themselves, may be protecting against breast cancer.
Researchers have discovered how a drug that starves cancer cells of an essential amino acid kills them. The study's findings suggest using this approach may spare patients from chemotherapy toxicity.
A study published in the New England Journal of Medicine found that women with mutations in the PALB2 gene have a one in three chance of developing breast cancer by age 70. The study analyzed data from 154 families and found that risks were higher for those with family history of breast cancer.
A new £6 million initiative is being launched to support cutting-edge research on cancer prevention. The project aims to build capacity in prevention science, combining lifestyle changes and interdisciplinary collaboration to reduce cancer cases.
The prostate cancer risk calculator has been updated to provide a more nuanced result, helping men understand their risk of low-grade and high-grade prostate cancer. The new calculator incorporates current risk factors and an advanced statistical model to distinguish between the prediction of low-grade and high-grade disease.
Researchers at Cancer Research UK have found a new use for an old drug, rapamycin, in shrinking and stopping the spread of a specific type of pancreatic cancer tumour. The study suggests that targeting mTOR dependency may be a key to tailoring treatment to individual patients.
A study found that retinoblastoma protein is less active in male brain cells, leading to higher brain tumor rates and poorer survival rates. The researchers believe this discovery could lead to more effective therapies and treatments.
University of Michigan researchers identified a protein called TRIP13 that enables cancer cells to repair themselves and survive despite chemotherapy. The team found an existing chemical compound that can block this process, potentially increasing the effectiveness of cancer treatment and improving patient survival rates.
Scientists at Barts Cancer Institute have identified a molecule called focal adhesion kinase (FAK) that signals the body to repair itself after chemotherapy or radiotherapy. Removing FAK from blood vessels in melanoma and lung cancer models made treatments more effective, suggesting that targeting this molecule could boost cancer therapy.
Researchers identified a core signalling system, the hippo pathway, and discovered how Merlin suppresses it within the nucleus. This understanding paves the way for developing effective drug therapies to treat nervous system tumours.
Researchers reveal detailed images of anaphase-promoting complex (APC/C), a protein that controls mitosis. The discovery could lead to new cancer drugs by identifying binding sites for future treatments.
A study has identified over 27,000 endogenous retroviruses preserved in the genomes of 38 mammal species, including humans. Larger animals have fewer ERVs, suggesting they may have evolved mechanisms to combat cancer-causing mutations.
A decade of research led by Dr. Tak Mak identified PLK4 as a promising therapeutic target for breast cancer treatment and developed a small molecule inhibitor to block it. The study showed significant antitumor activity in preclinical models, offering hope for personalized cancer medicine.
A new skin gel form of tamoxifen has been developed and tested on women with non-invasive breast cancer, reducing cancer cell growth while minimizing side effects. The gel application was found to be effective in reducing blood clot risk associated with oral tamoxifen, offering a safer treatment option.
A*STAR's Bioprocessing Technology Institute has partnered with Roche to develop new cancer treatments using novel antibodies that can directly target and destroy cancer cells. The partnership aims to improve cancer detection and treatment, offering a potential breakthrough in cancer therapy.
The foundation has granted over $3.3 million to support the research of 16 early-career investigators pursuing novel ideas in cancer research. The recipients will focus on developing new treatments and understanding the underlying mechanisms of various types of cancers.
Researchers isolated breast cancer cells from patients' blood and expanded them in the lab, identifying new mutations and drug susceptibility. The study found a promising drug, Ganetspib, effective in killing tumor cells with specific genetic mutations.
Researchers at Massachusetts General Hospital developed a microchip-based device to capture and culture circulating tumor cells (CTCs) for genetic analysis and drug testing. The study found that cultured CTCs accurately reflect a tumor's genetic mutation over time, revealing new mutations and potential drug targets.
Researchers at the University of Manchester discovered a new drug, AZD3965, effective in treating small cell lung cancer. The treatment approach exploits the change in energy production in tumours, targeting monocarboxylate transporters involved in lactate movement.
A drug candidate developed to treat sickle cell disease has been acquired by Baxter International, advancing its clinical development activities. Aes-103 significantly reduces patients' pain in Phase II clinical trials, offering a potential breakthrough treatment.
Researchers at Rockefeller University have identified a protein called TARBP2 that triggers breast cancer's spread by blocking other proteins linked to neurodegeneration. This finding suggests new cancer therapies targeting this 'master regulator' could be effective.
A study by UT Southwestern found a five-fold increase in cancer patients using MyChart from 2009 to 2015, with those over 60 making up the majority of frequent users. The technology's convenience and ease of use contribute to its widespread adoption among this demographic.
Researchers have uncovered mutations in a cell-signaling pathway that plays a role in forming tumors. These genetic changes may expand treatments for patients, as drugs targeting some of these pathways are already available or in clinical trials.
A study found that genetic mutations in liver cells drive tumor formation in iCCA, with mutant proteins impairing liver cell development and increasing the risk of metastasis. Researchers discovered a potential treatment option by targeting IDH1/2 mutations, opening a new line of investigation for biomarkers and life-saving decisions.
A new study published in PNAS found that metabolic processes are significantly increased during sleep deprivation, with 27 metabolites found at higher levels. This discovery could be crucial when looking at the best time of day to test for diseases such as cancer and heart disease.
A phase 3 study of everolimus failed to improve overall survival in patients with advanced hepatocellular carcinoma, a type of liver cancer. In contrast, sorafenib is the only systemic therapy shown to significantly improve overall survival.
The EORTC presents a European solution for effective cancer drug development through collaborative molecular screening platforms. These platforms enable efficient access to new therapeutic agents and adapt clinical research to individual patient needs.
Researchers at H. Lee Moffitt Cancer Center & Research Institute developed a liquid chromatography-multiple reaction monitoring mass spectrometry assay to analyze biomarkers in blood and tissue, helping identify therapeutic targets for melanoma treatment. The study identified alterations in cell signaling pathways in drug-resistant cells.
Scientists have discovered where microtubules form inside the mitotic spindle and how their starting points are transported to opposite poles. This breakthrough provides a better understanding of cell division and paves the way for more effective cancer treatments.
A recent study published in Annals of Internal Medicine found that current standard medical guidelines for childhood cancer survivors can be reduced, saving large cost-savings and little reduction in overall quality of patient care. The study suggests that screenings can be safely done cost-effectively and improve the quantity of patie...
A study by Wake Forest Baptist Medical Center found that St. John's wort use was associated with 28% of potentially harmful combinations in analyzed data. The herbal supplement can reduce the effectiveness of various medications, leading to impaired treatment outcomes and increased risk of conditions like serotonin syndrome.
A 30-year follow-up study found no link between fertility drugs and breast, ovarian, and uterine cancers, except for extended use of clomiphene citrate. The study of 12,193 women treated for infertility showed a higher risk of invasive breast cancer with clomiphene use in 12 or more treatment cycles.
A new study found that HIV-infected people diagnosed with early-stage cancer are two to four times more likely to receive inadequate treatment. The research suggests that a lack of clinical trial data and guidelines on treating HIV patients with cancer may contribute to this disparity.
Adding cetuximab or bevacizumab to combination chemotherapy improves survival for patients with KRAS wild-type untreated colorectal cancer, with both treatments offering approximately 30-month overall survival. Genetic testing is crucial to determine the benefit of these treatments.
Researchers discover synthetic triterpenoids suppress colon cancer onset by impeding inflammation and increasing 15-hydroxyprostaglandin dehydrogenase gene expression. Oral administration in mice shows promise for chemoprevention, with potential to delay or halt colon cancer development.
Researchers have discovered a partnership between MYC and non-coding RNA PVT1 that fuels cancer cells. This finding could lead to the development of drugs targeting PVT1, potentially controlling major cancer genes like MYC.
Researchers developed a hydrogel that releases chemotherapy drugs in short bursts triggered by ultrasound, improving cancer treatment outcomes. The self-healing gel approach offers a more effective and minimally invasive method for delivering drugs at the right place and time.
Saint Louis University researchers have discovered a molecular pathway that causes painful chemotherapy side effects and found a potential way to block it. A drug already approved for treating multiple sclerosis may also alleviate chemotherapy-induced peripheral neuropathy (CIPN) without affecting the medication's anticancer properties.
Early exposure to ultraviolet radiation from indoor tanning increases the risk of basal cell carcinomas in young people. Researchers found that teens and young adults who use indoor tanning devices are more likely to develop BCC, especially on the torso.
Supercomputer simulations reveal that Ras protein clusters warp cell membranes, leading researchers to investigate the design of new anticancer drugs. The study uses coarse-grained molecular dynamics simulations to understand the dynamics of Ras proteins and their interaction with the membrane.
A new tool, COST (COmprehensive Score for financial Toxicity), measures a patient's risk for and ability to tolerate financial stress in cancer care. The study found that financial toxicity affects 30% of cancer survivors, with significant impact on workability and quality of life.
Researchers discovered a genetic partnership between KRAS and YAP1, enabling cancer cells to survive in the absence of KRAS. This 'escape mechanism' must be blocked alongside shutting down oncogene KRAS to kill tumor cells.
Researchers at St. Joseph's Hospital and Medical Center discovered a new treatment for ovarian cancer that improves response rates and prolongs time until cancer recurrence. Trebananib, a peptide-Fc fusion protein, targets angiogenesis by inhibiting angiopoietin 1 and 2 binding to the Tie2 receptor.
Researchers developed a vaccine that triggered the growth of immune cell nodules within pancreatic tumors, reprogramming these intractable cancers. The vaccine, GVAX, consists of irradiated tumor cells modified to recruit immune cells, and boosted activity of molecular mechanisms that inhibit cancer-fighting immune cells.
A study of over 56,000 patients with inflammatory bowel disease found no association between TNF inhibitor use and increased cancer risk. However, the authors emphasize the need for continued long-term follow-up to monitor potential risks.
Researchers are testing the safety and effectiveness of AG-120, a new drug designed for patients with IDH1 gene mutations, in a clinical trial at the Virginia G. Piper Cancer Center Clinical Trials. The study aims to improve treatment options for patients with solid tumors, including brain tumors and gallbladder bile duct cancer.
A meta-analysis of 43 studies found that sedentary behavior increases the risk of colon, endometrial, and lung cancers. The risk increases with sitting time, even among physically active individuals, suggesting a detrimental impact on cancer prevention.
Researchers discovered that switching off and then reactivating the Pax5 gene can reverse cancer in a common childhood leukemia model. Restoring its function enables normal blood cell development and cures the disease. The findings offer a promising new strategy for treating leukemia with fewer side effects.